Cantor Fitzgerald initiated coverage of CytomX Therapeutics (CTMX) with an Overweight rating and $6 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTMX:
- CytomX Therapeutics assumed with an Overweight at Barclays
- CytomX Therapeutics initiated with an Overweight at Barclays
- Barclays sees ‘significant potential’ in CytomX’s CX-2051 despite safety event
- CytomX trial ongoing despite grade five event, says Oppenheimer
- CytomX Therapeutics Updates on CX-2051 Phase 1 Study